IMRX

3.3802.03%
AW

Andrew W. Gengos

CFO & Treasurer

Mr. Andrew W. Gengos, M.B.A. was Director of Seneca Therapeutics, Inc. from September 2025 to 2026. Mr. Gengos is Chief Financial Officer of Immuneering Corporation from July 16, 2026 and serves as Treasurer from July 16, 2026. Mr. Gengos was CFO & Chief Business Officer of Athira Pharma, Inc. from May 10, 2023 to October 1, 2024. Mr. Gengos served as Chief Financial Officer of Terns Pharmaceuticals, Inc. since February 2025 until May 2026 and served as Treasurer and was Head of Corporate Development since 2025. He served as Advisor at Turn Therapeutics Inc. (Former name Global Health Solutions, Inc.) and serves as its Independent Director since January 2020. Mr. Gengos serves as Chief Financial Officer and Chief Business Officer at Athira Pharma, Inc. since May 18, 2023. He served as Chief Business Officer at Cyteir Therapeutics, Inc. since February 24, 2020 until February 03, 2023 and served as its Secretary. Mr. Gengos served as Chief Business Officer and Chief Financial Officer of AOBiome Therapeutics from January 2019 to December 2019. He served as Chief Operating Officer and Head of Corporate Development at Synlogic, Inc. since October 2017 until January 15, 2019. Mr. Gengos is responsible for all corporate and business development activities at Synlogic. He has senior leadership experience in the biotechnology and pharmaceutical industries, holding key positions at companies focused on advancing innovative products and technologies. He serves on the board of directors of Turn Therapeutics, a biotechnology company. Mr. Gengos served as the Chief Executive Officer and President of ImmunoCellular Therapeutics, Ltd. from December 3, 2012 to December 14, 2016. Mr. Gengos served as the Chief Executive Officer and President of Neuraltus Pharmaceuticals, Inc. since February 2010. He joined Neuraltus after more than seven years with Amgen, where he served as Vice President of Strategy and Corporate Development and was responsible for facilitating the development of its corporate strategy and managing all M&A, Licensing, Spinout and Venture Capital activities. In addition. Mr. Gengos led the execution of strategic projects and supported the long range planning process for Amgen. He served as Chief Business Officer of Dynavax Technologies Corporation. He served as Vice President and Chief Financial Officer of Dynavax Technologies Corporation since October 2000, where he was responsible for its business functions including finance and accounting, fundraising, budgeting and planning and business development. He joined Dynavax Technologies Corporation in 2000. From January 1999 to 2000. Mr. Gengos was employed by Chiron Corporation (now Novartis), where he served as a Vice President of Strategy, Vice President and Senior Director of Corporate Development. From 1991 to October 1998, he worked for McKinsey & Company as a Consultant in its healthcare practice and also served as its Senior Engagement Manager. He served as a Member of Advisory Board at PBS Biotech Inc. Mr. Gengos served as a Director of ImmunoCellular Therapeutics, Ltd. from December 03, 2012 to June 16, 2017. He served as a Director of Allozyne, Inc., Neuraltus Pharmaceuticals, Inc. and Relypsa, Inc. In 1991. Mr. Gengos received an Master's of Business Administration with an emphasis on Business Strategy and Finance from the Anderson Graduate School of Business at the University of California - Los Angeles in 1991. He received his BS degree in Chemical Engineering from Massachusetts Institute of Technology (MIT) in 1986.

Positions